Ciclosporin in psoriasis clinical practice: An international consensus statement

C. E M Griffiths, L. Dubertret, C. N. Ellis, A. Y. Finlay, A. F. Finzi, V. C. Ho, A. Johnston, A. Katsambas, A. E. Lison, J. M. Naeyaert, H. Nakagawa, C. Paul, F. Vanaclocha

    Research output: Contribution to journalArticlepeer-review


    The main recommendations for the use of ciclosporin in the management of psoriasis are: (i) intermittent short courses (average of 12 weeks duration) of ciclosporin are preferable; (ii) ciclosporin should be given in the dose range 2.5-5.0 mg kg-1 day-1 (doses greater than 5.0 mg kg -1 day-1 should only be given in exceptional circumstances); (iii) treatment regimens should be tailored to the needs of each patient; (iv) selection of patients should take into account psychosocial disability, as well as clinical extent of disease and failure of previous treatment; (v) each patient's renal function (as measured by serum creatinine) should be thoroughly assessed before and during treatment; (vi) each patient's blood pressure should be carefully monitored before and during treatment; (vii) adherence to treatment guidelines substantially reduces the risk of adverse events; (viii) long-term continuous ciclosporin therapy may be appropriate in a subgroup of patients; however, duration of treatment should be kept below 2 years whenever possible; and (ix) when long-term continuous ciclosporin therapy is necessary, annual evaluation of glomerular filtration rate may be useful to accurately monitor renal function.
    Original languageEnglish
    Pages (from-to)11-23
    Number of pages12
    JournalBritish Journal of Dermatology, Supplement
    Issue number67
    Publication statusPublished - May 2004


    • Calcineurin inhibitor
    • Ciclosporin
    • Clinical practice
    • Consensus
    • Psoriasis


    Dive into the research topics of 'Ciclosporin in psoriasis clinical practice: An international consensus statement'. Together they form a unique fingerprint.

    Cite this